Hyqvia is the only subcutaneous immune globulin infusion that can be administered once per month.
FDA Approves Takeda’s Hyqvia for Maintenance of Chronic Inflammatory Demyelinating Polyneuropathy
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours